Biotech RadarJobs updated

COMPANY

CAGE Bio

HQ: San Carlos, CA source · cagebio.com ↗

Clinical Phase 2

Keywords: dermatology atopic dermatitis alopecia areata vitiligo Rosacea Fungal Infection Onychomycosis Tinea Unguium Bacterial Overgrowth Erythema Sensitisation CGB-400 CGB-S-100

Location: San Carlos, CA · source · Apr 30, 2025

Profile checked Oct 10, 2026

10Trials (company is sponsor)

Timeline

  1. Trial start 1: A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo source ↗
  2. Trial start Phase 2: A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis source ↗
  3. Trial start 2: Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis source ↗
  4. Trial start Phase 1/Phase 2: Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis source ↗
  5. Trial start —: An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection source ↗
  6. Trial start Phase 2: CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea source ↗
  7. Trial start Early phase 1: Clinical Evaluation of the Residual Antimicrobial Activity source ↗
  8. Trial start Phase 1: CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes source ↗
  9. Trial start Phase 1: CGB-400 for the Reduction of Facial Redness source ↗
  10. Trial start Not phased (device or behavioral study): 50 Human Subject Repeat Insult Patch Test source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT06810050Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis2CompletedDec 18, 2024Aug 30, 2025 (actual)
NCT05202366An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal InfectionNot listedCompletedFeb 8, 2022Aug 8, 2024 (actual)
NCT06923228A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic DermatitisPhase 2CompletedApr 21, 2025Jul 30, 2025 (actual)
NCT04886739CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of RosaceaPhase 2CompletedMay 7, 2021Dec 22, 2021 (actual)
NCT07357870A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo1RecruitingJul 25, 2025Nov 30, 2026 (estimated)
NCT05487963Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic DermatitisPhase 1/Phase 2CompletedNov 9, 2022Jun 30, 2023 (actual)
NCT04508205CGB-400 for the Reduction of Facial Redness and Bumps and BlemishesPhase 1CompletedOct 26, 2018Apr 18, 2019 (actual)
NCT04508660CGB-400 for the Reduction of Facial RednessPhase 1CompletedOct 26, 2018Apr 18, 2019 (actual)
NCT04495920Clinical Evaluation of the Residual Antimicrobial ActivityEarly phase 1CompletedJun 16, 2020Jul 13, 2020 (actual)
NCT0449867650 Human Subject Repeat Insult Patch TestNot phased (device or behavioral study)CompletedJan 18, 2017Feb 8, 2017 (actual)
Feedback